FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL

The trial enrolled 238 patients, randomised 1:1 to receivethe therapy or an investigator-chosen regimen. Credit: Motortion Films/Shutterstock.com.